A phase II, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: A Gynecologic Oncology Group partners study

Journal article

Peer reviewed

B.J. Monk, M.F. Brady, C. Aghajanian, H. Lankes, T. Rizack, J.W. Leach, J.M. Fowler, R.V. Higgins, P. Hanjani and M.A. Morgan

Gynecologic oncology, Vol.145, pp.220-221

06/01/2017

Metrics

Title: A phase II, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: A Gynecologic Oncology Group partners study
Creators: B.J. Monk - University of Arizona
M.F. Brady - University at Buffalo, State University of New York
C. Aghajanian - Cornell University
H. Lankes - Gynecologic Oncology Group
T. Rizack - Women & Infants Hospital of Rhode Island
J.W. Leach - Metro-Minnesota Community Oncology Research Consortium
J.M. Fowler - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
R.V. Higgins - Carolinas Medical Center
P. Hanjani - Abington Memorial Hospital
M.A. Morgan - University of Pennsylvania
Publication Details: Gynecologic oncology, Vol.145, pp.220-221
Identifiers: 991005969025102656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article